Clinical Trials

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05498896 2026-05-08

BARBICAN

146 enrolled

Triple Negative Breast Neoplasms

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

40 enrolled

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03756298 2026-04-23

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

284 enrolled

Triple Negative Breast Neoplasms

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

37 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT04770272 2026-01-12

neoMono

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT06690840 2026-01-05

AZALEA

Phase 2 Recruiting

45 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

184 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

33 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03371017 2025-11-12

IMpassion132

595 enrolled 37 charts

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

914 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06067061 2025-06-11

neoBREASTIM

Phase 1/2 Terminated

2 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Triple Negative Breast Neoplasms

NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Phase 1/2 Terminated

222 enrolled 49 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03206203 2024-12-12

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

106 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03164993 2024-10-15

ALICE

68 enrolled

Breast Neoplasms, Neoplasms, Triple Negative Breast Neoplasms

NCT06342037 2024-09-19

TONIC-3

Phase 2 Recruiting

60 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03498716 2024-08-21

IMpassion030

Phase 3 Terminated

2,199 enrolled 13 charts

Triple Negative Breast Neoplasms

NCT04408118 2024-06-04

ATRACTIB

100 enrolled

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03256344 2024-05-14

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Phase 1 Completed

36 enrolled 16 charts

BreastGastrointestinal

Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03281954 2024-04-08

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

1,550 enrolled

Triple Negative Breast Neoplasms

NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

242 enrolled 12 charts

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

NCT03125902 2024-03-26

IMpassion131

653 enrolled 33 charts

Triple Negative Breast Neoplasms

NCT02620280 2024-03-06

NeoTRIPaPDL1

278 enrolled

Carcinoma, Ductal, Breast, Triple Negative Breast Neoplasms

NCT04739670 2024-03-01

BELLA

31 enrolled

Recurrence, Triple Negative Breast Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

28 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT05266937 2024-02-01

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

49 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04690855 2023-12-04

TARA

1 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03197935 2023-10-26

IMpassion031

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

BreastGenitourinaryThoracic

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Phase 1 Completed

83 enrolled

Phase EARLY_PHASE1 Withdrawn

Triple Negative Breast Neoplasms

NCT04249167 2023-01-06

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Phase EARLY_PHASE1 Terminated

Triple Negative Breast Neoplasms

NCT04102618 2022-08-15

AWARE-1

26 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02425891 2022-07-19

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

902 enrolled 27 charts 1 FDA

Triple Negative Breast Neoplasms

NCT03952325 2021-07-30

CONTESSA TRIO

294 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03292172 2020-11-06

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Phase 1 Terminated

36 enrolled

Triple Negative Breast Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.